Edition:
India

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

12.46USD
1:30am IST
Change (% chg)

$-0.07 (-0.56%)
Prev Close
$12.53
Open
$12.44
Day's High
$12.63
Day's Low
$12.18
Volume
67,535
Avg. Vol
95,053
52-wk High
$15.08
52-wk Low
$5.45

Chart for

About

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $404.27
Shares Outstanding(Mil.): 48.71
Dividend: --
Yield (%): --

Financials

  CCXI.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.62 -- --
ROI: -27.86 14.84 14.38
ROE: -59.68 16.34 16.07

BRIEF-Chemocentryx Q1 Revenue $9.5 Million Versus $8.2 Million

* CHEMOCENTRYX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

10 May 2018

BRIEF-Chemocentryx Q4 Revenue $56.3 Million Versus $4.9 Million

* CHEMOCENTRYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

09 Mar 2018

BRIEF-Chemocentryx Secures Up To $100 Million In New Capital Commitments

* CHEMOCENTRYX SECURES UP TO $100 MILLION IN NEW CAPITAL COMMITMENTS

04 Jan 2018

BRIEF-ChemoCentryx Says EMA Accepts Vasculitis Drug Avacopan For Conditional Review

* AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

04 Jan 2018

Competitors

Earnings vs. Estimates